-

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Affirm Holdings, Inc. (AFRM) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Affirm Holdings, Inc. (“Affirm”) (NASDAQ: AFRM) securities between February 12, 2021 through December 15, 2021 (the “Class Period”). Investors have until February 6, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Affirm is a financial technology company that operates a platform for digital and mobile-first commerce.

On December 16, 2021, the Consumer Financial Protection Bureau (“CFPB”) announced that it had launched an inquiry into Affirm’s BNPL payment service, along with four other companies offering BNPL. The CFPB indicated that it was concerned about how BNPL leads to “accumulating debt, regulatory arbitrage, and data harvesting,” and is seeking data on the risks and benefits of the products. In a statement addressing BNPL services, the CFPB Director stated, “[t]he consumer gets the product immediately but gets the debt immediately too.” On this news, the price of Affirm shares declined by $11.74 per share, or approximately 10.58%, from $110.98 per share to close at $99.24 on December 16, 2021.

If you purchased or otherwise acquired Affirm securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:AFRM

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Social Media Profiles
More News From Kirby McInerney LLP

RAL INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Ralliant Corporation

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Ralliant Corporation (“Ralliant” or the “Company”) (NYSE:RAL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 4, 2026, Ralliant reported fourth quarter and full year 2025 results, revealing a “$1.4 billion non-cas...

KDDIY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving KDDI Corporation

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of KDDI Corporation (“KDDI” or the “Company”) (OTC:KDDIY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 6, 2026, KDDI posted an announcement on its website entitled “Notice Regarding Expectation that Disclosure of...

INVESTOR ALERT: Securities Class Action Filed Against Corcept Therapeutics Incorporated – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) securities during the period of October 31, 2024 through December 30, 2025, inclusive (“the Class Period”). If you suffered a loss on your Corcept investments, you have until April 21, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff app...
Back to Newsroom